Physician profile

Avery E Klepacki Allen

Advanced Practice Midwife · Portland, OR

NPI 1073019071

$289.69

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Advanced Practice Midwife

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$59.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $63.78 2021-2023
Hologic Sales and Service, LLC $60.03 2022-2023 Aptima, Thinprep 2000 Processor
Daiichi Sankyo INC. $49.31 2021-2022
Medicem INC. $34.30 2021
Bayer Healthcare Pharmaceuticals INC. $27.87 2022
Mayne Pharma Commercial LLC $22.77 2021
Exeltis, USA INC. $16.06 2022
Therapeuticsmd, INC. $15.57 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Avery E Klepacki Allen

$289.69

in general payments reported 2019-2025

Years
2021-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/10887252/avery-e-klepacki-allen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.